ABBV-706 is an ADC targeting SEZ6 developed by AbbVie. It is linked to a topoisomerase 1 inhibitor (TOP1i) via a ...

Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, discusses how early data from ABBV-706 shows up to 50% ...

A young university student whose repeated symptoms of stomachache, nausea, vomiting, and weight loss were dismissed by ...

Appendix cancer is a rare but increasingly recognized malignancy, often discovered incidentally during surgery for presumed ...

A frontline health worker said running helped save his life after he was diagnosed with a rare form of cancer and a heart ...

Pedro Valencia, VP, asset strategy, leadership, oncology, AbbVie, outlines how the company is accelerating development across ...

Long-term efficacy and safety data on PALSONIFYTM (paltusotine) in acromegaly to be presented, including evidence of both ...

Appendix cancer, once rare, is now rising sharply among younger people. Firstpost brings out an expert’s views on the risk ...

Lantheus Holdings offers a compelling bull case, with PYLARIFY and DEFINITY driving valuation and strong growth prospects.

People are beginning to realize that dogs share a lot more with humans than just their homes and habits. Some spontaneously occurring cancers in dogs are genetically very similar to those in people ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that the drug be authorised to treat unresectable ...

ESTEVE has entered into an agreement with Sanofi to acquire Caprelsa® (vandetanib) rights in more than 50 countries, a ...